<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=3993628&amp;fmt=gif">

The HTX-011 (XYNRELEF®) Story

Confirming the mechanisms of action in a translational model of incisional pain.





Watch Webinar

About this webinar:

Obtaining consistent efficacy beyond 12–24 hours with local anesthetics, including extended-release formulations, has been a challenging goal. Inflammation following surgery lowers the pH of affected tissues, reducing neuronal penetration of local anesthetics. HTX-011, a local anesthetic combining bupivacaine and low-dose meloxicam was developed to reduce postsurgical pain through 72 hours using novel extended-release polymer technology.

This webinar reviews preclinical and clinical data confirming the mechanism of action for HTX-011.

HTX webinar

Sigal Meilin, PhD
CSO MD Biosciences


Watch the On-demand Webinar now.